Company / R&D per Share
CRISPR Therapeutics AG R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$3.32
FY2025
5-year range
$3.32 / $6.00
FY2021-FY2025
Trend
-14.3%
vs FY2024
Sector context
#64 of 207
Health Care
What the data says
At $3.32, CRISPR Therapeutics AG's r&d per share ranks #64 of 207 in the Health Care sector. R&D per Share has declined for 3 consecutive years, from $6.00 in FY2022 to $3.32 in FY2025.
Based on SEC 10-K filings.
3.32 in FY2025 with a 5-year CAGR of -1.8%.
Declined from $4.93 to $3.32 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -17.9%
- 5-Year CAGR
- -1.8%
- 10-Year CAGR
- -
Sector benchmark
#64 of 207 in Health CareTop 31% of 207This company $3.32 Sector average $12.26
▼
-72.9% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 14.3% year-over-year.
- Ranks #64 out of 207 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.32 | -14.3% |
| FY2024 | $3.88 | -21.4% |
| FY2023 | $4.93 | -17.7% |
| FY2022 | $6.00 | +30.1% |
| FY2021 | $4.61 | +26.5% |
| FY2020 | $3.64 | +5.3% |
| FY2019 | $3.46 | +23.4% |
| FY2018 | $2.80 | +59.5% |
| FY2017 | $1.76 | -77.0% |
| FY2016 | $7.64 | +206.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026